

## Impact of plan-level access restrictions on adherence and effectiveness of biologics among patients with rheumatoid or psoriatic arthritis

Pharmacoeconomics

Natalie Boytsov, Xiang Zhang, Kristin A. Evans, Barbara H. Johnson

Corresponding Author: Natalie Boytsov, Eli Lilly and Company, boytsov\_natalie\_n@lilly.com

### Online Resource 2: Additional baseline demographic characteristics of RA patients

	All RA Patients N=3,993	Access Restrictions				P value (Any vs None)
		Any N=1,364	PA Only N=403	Step Therapy <sup>a</sup> N=961	None N=2,629	
<b>Region, N (%)</b>						
Northeast	484 (12.1%)	132 (9.7%)	49 (12.2%)	83 (8.6%)	352 (13.4%)	0.001
North Central	845 (21.2%)	192 (14.1%)	27 (6.7%)	165 (17.2%)	653 (24.8%)	<0.001
South	2124 (53.2%)	844 (61.9%)	194 (48.1%)	650 (67.6%)	1280 (48.7%)	<0.001
West	533 (13.3%)	195 (14.3%)	133 (33.0%)	62 (6.5%)	338 (12.9%)	0.205
Unknown	7 (0.2%)	1 (0.1%)	0 (0.0%)	1 (0.1%)	6 (0.2%)	0.000
<b>Urban residence, N (%)</b>						
Urban	3422 (85.7%)	1050 (77.0%)	289 (71.7%)	761 (79.2%)	2372 (90.2%)	<0.001
Rural	564 (14.1%)	313 (22.9%)	114 (28.3%)	199 (20.7%)	251 (9.5%)	<0.001
Unknown						
<b>Insurance plan type, N (%)</b>						
Comprehensive	209 (5.2%)	27 (2.0%)	1 (0.2%)	26 (2.7%)	182 (6.9%)	<0.001
EPO/PPO	2272 (56.9%)	749 (54.9%)	298 (73.9%)	451 (46.9%)	1523 (57.9%)	0.068
POS/POS with capitation	337 (8.4%)	104 (7.6%)	26 (6.5%)	78 (8.1%)	233 (8.9%)	0.182
HMO	255 (6.4%)	139 (10.2%)	41 (10.2%)	98 (10.2%)	116 (4.4%)	<0.001
CDHP/HDHP	878 (22.0%)	313 (22.9%)	19 (4.7%)	294 (30.6%)	565 (21.5%)	0.292
Unknown	42 (1.1%)	32 (2.3%)	18 (4.5%)	14 (1.5%)	10 (0.4%)	<0.001

Notes: <sup>a</sup>with or without PA. Abbreviations: CDHP, consumer driven health plan; EPO, exclusive provider organization; HDHP, high-deductible health plan; HMO, health maintenance organization; PA, prior authorization; POS, point of service; PPO, preferred provider organization; RA, rheumatoid arthritis